Biocytogen Enters Platform Licensing Agreement with Taisho to Expand Use of RenNano® Antibody Discovery Technology Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a global biotechnology company recognized for its innovation in antibody-based…
PepGen Reports Encouraging Phase 2 Data for PGN-EDODM1 in Myotonic Dystrophy Type 1, Advances Higher-Dose Cohort in FREEDOM2 Trial PepGen Inc., a clinical-stage biotechnology company focused on advancing next-generation oligonucleotide…
DiaMedica Therapeutics Reports 2025 Financial Results and Advances Clinical Pipeline in Preeclampsia and Acute Ischemic Stroke DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for serious…
Emmaus Life Sciences Announces Annual Financial Performance Update Emmaus Life Sciences Reports 2025 Financial Results, Navigates Revenue Pressure with Cost Discipline and Strategic Shift Emmaus Life Sciences, Inc., a commercial-stage…
Roche Launches cobas MPX-E, a 4-in-1 Donor Screening Assay to Strengthen Global Blood Supply Safety Roche has announced the availability of its cobas® MPX-E assay, a next-generation qualitative in vitro…
Incyte Reports Positive 54-Week Late-Breaking Povorcitinib Data in Hidradenitis Suppurativa at AAD 2026 Incyte has reported new long-term findings from its pivotal Phase 3 STOP-HS clinical development program, highlighting the…
Bristol Myers Squibb Reports Positive Phase 3 SCOUT-HCM Results for Camzyos in Adolescents with Symptomatic oHCM Bristol Myers Squibb has announced compelling results from its pivotal Phase 3 SCOUT-HCM clinical…
Phase 2 CADENCE Trial Shows Positive Results, Establishing WINREVAIR™ as a Proof-of-Concept Therapy in CpcPH and HFpEF Merck & Co.—known as MSD outside the United States and Canada—has unveiled comprehensive…
Bepirovirsen advances to regulatory review by the European Medicines Agency as a promising first-in-class therapy for chronic hepatitis B GSK plc has announced a significant regulatory milestone as the European…
Novartis Agrees to Acquire Excellergy, Inc. to Strengthen Allergy Leadership with Next-Generation Anti-IgE Innovation Novartis has announced a strategic agreement to acquire Excellergy, a privately held biotechnology company focused on…
AbbVie to Present New Clinical and Real-World Evidence Advancing Care Standards in Immune-Mediated Skin Diseases at the AAD Annual Meeting 2026 AbbVie has announced a comprehensive slate of new research…
Eli Lilly and Company Reports Up to Four Years of Sustained Disease Control with EBGLYSS (lebrikizumab-lbkz) in Moderate-to-Severe Atopic Dermatitis Eli Lilly and Company has unveiled compelling new long-term data…